The Asia Pacific Lymphoma Therapeutics Market would witness market growth of 8.2% CAGR during the forecast period (2023-2029).
The etiology of the majority of lymphoma cases remains unknown. However, certain individuals are deemed to be at an elevated risk. These individuals have immunodeficiency, which may be a result of a weakened immune system due to HIV or the use of an immune system-suppressing medication following an organ transplant. In addition, individuals diagnosed with specific autoimmune conditions, like celiac disease and rheumatoid arthritis, are at a heightened risk for developing lymphoma.
The incidence of lymphoma tends to increase with age. Certain types are prevalent among young children and infants. The incidence of lymphoma is gender-biased, with men being at a higher risk than women. However, certain subtypes of NHL have a higher propensity to manifest in women. Individuals who have contracted infections such as HTLV-1, H. pylori, hepatitis C, or EBV are linked to a higher risk.
Individuals who come into contact with chemicals present in fertilizers, pesticides, and herbicides are more prone to it. Exposure to nuclear radiation may elevate the likelihood of developing NHL. Obesity can increase the likelihood of lymphoma development in individuals. Having a sibling diagnosed with this kind of cancer increases the risk of developing it. Mononucleosis can be caused by an EBV infection. This condition may elevate the likelihood of developing lymphoma.
In India, there are notable differences in the demographic and clinical characteristics of patients with lymphoma when compared to developed nations. These differences include a lower median age of 54 years, a higher male-to-female ratio, a higher proportion of patients with B-symptoms. Also, they have a poor ECOG performance status at diagnosis, a higher frequency of diffuse large B-cell lymphomas, a lower frequency of follicular NHL, and a higher frequency of T-cell type. In addition, the mortality rate attributed to NHL is comparatively higher in India as compared to other regions of the world. Hence, the high cases of non-Hodgkin's lymphoma will increase the demand for numerous therapeutic methods for its treatment and thereby propel the market growth of lymphoma therapeutics in APAC.
The China market dominated the Asia Pacific Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,818.6 million by 2029. The Japan market is estimated to grow a CAGR of 7.6% during (2023 - 2029). Additionally, The India market would experience a CAGR of 8.9% during (2023 - 2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Lymphoma Therapeutics Market is Projected to reach USD 24.9 Billion by 2029, at a CAGR of 7.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
Scope of the Study
Market Segments Covered in the Report:
By Treatment Type
- Immune Therapy
- Target Therapy
- Chemotherapy
- Radiation Therapy
By Disease Type
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Lymphoma Therapeutics Market, by Treatment Type
1.4.2 Asia Pacific Lymphoma Therapeutics Market, by Disease Type
1.4.3 Asia Pacific Lymphoma Therapeutics Market, by Route of Administration
1.4.4 Asia Pacific Lymphoma Therapeutics Market, by Distribution Channel
1.4.5 Asia Pacific Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Asia Pacific Lymphoma Therapeutics Market by Treatment Type
4.1 Asia Pacific Immune Therapy Market by Country
4.2 Asia Pacific Target Therapy Market by Country
4.3 Asia Pacific Chemotherapy Market by Country
4.4 Asia Pacific Radiation Therapy Market by Country
Chapter 5. Asia Pacific Lymphoma Therapeutics Market by Disease Type
5.1 Asia Pacific Non-Hodgkin Lymphoma Market by Country
5.2 Asia Pacific Hodgkin Lymphoma Market by Country
Chapter 6. Asia Pacific Lymphoma Therapeutics Market by Route of Administration
6.1 Asia Pacific Injectable Market by Country
6.2 Asia Pacific Oral Route Market by Country
Chapter 7. Asia Pacific Lymphoma Therapeutics Market by Distribution Channel
7.1 Asia Pacific Hospital Pharmacies Market by Country
7.2 Asia Pacific Retail Pharmacies Market by Country
7.3 Asia Pacific Others Market by Country
Chapter 8. Asia Pacific Lymphoma Therapeutics Market by Country
8.1 China Lymphoma Therapeutics Market
8.1.1 China Lymphoma Therapeutics Market by Treatment Type
8.1.2 China Lymphoma Therapeutics Market by Disease Type
8.1.3 China Lymphoma Therapeutics Market by Route of Administration
8.1.4 China Lymphoma Therapeutics Market by Distribution Channel
8.2 Japan Lymphoma Therapeutics Market
8.2.1 Japan Lymphoma Therapeutics Market by Treatment Type
8.2.2 Japan Lymphoma Therapeutics Market by Disease Type
8.2.3 Japan Lymphoma Therapeutics Market by Route of Administration
8.2.4 Japan Lymphoma Therapeutics Market by Distribution Channel
8.3 India Lymphoma Therapeutics Market
8.3.1 India Lymphoma Therapeutics Market by Treatment Type
8.3.2 India Lymphoma Therapeutics Market by Disease Type
8.3.3 India Lymphoma Therapeutics Market by Route of Administration
8.3.4 India Lymphoma Therapeutics Market by Distribution Channel
8.4 South Korea Lymphoma Therapeutics Market
8.4.1 South Korea Lymphoma Therapeutics Market by Treatment Type
8.4.2 South Korea Lymphoma Therapeutics Market by Disease Type
8.4.3 South Korea Lymphoma Therapeutics Market by Route of Administration
8.4.4 South Korea Lymphoma Therapeutics Market by Distribution Channel
8.5 Singapore Lymphoma Therapeutics Market
8.5.1 Singapore Lymphoma Therapeutics Market by Treatment Type
8.5.2 Singapore Lymphoma Therapeutics Market by Disease Type
8.5.3 Singapore Lymphoma Therapeutics Market by Route of Administration
8.5.4 Singapore Lymphoma Therapeutics Market by Distribution Channel
8.6 Malaysia Lymphoma Therapeutics Market
8.6.1 Malaysia Lymphoma Therapeutics Market by Treatment Type
8.6.2 Malaysia Lymphoma Therapeutics Market by Disease Type
8.6.3 Malaysia Lymphoma Therapeutics Market by Route of Administration
8.6.4 Malaysia Lymphoma Therapeutics Market by Distribution Channel
8.7 Rest of Asia Pacific Lymphoma Therapeutics Market
8.7.1 Rest of Asia Pacific Lymphoma Therapeutics Market by Treatment Type
8.7.2 Rest of Asia Pacific Lymphoma Therapeutics Market by Disease Type
8.7.3 Rest of Asia Pacific Lymphoma Therapeutics Market by Route of Administration
8.7.4 Rest of Asia Pacific Lymphoma Therapeutics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Bayer AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Approvals and Trials:
9.1.6 SWOT Analysis
9.2 Johnson & Johnson
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental &Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 Gilead Sciences, Inc.
9.3.1 Company overview
9.3.2 Financial Analysis
9.3.3 Research & Development Expenses
9.3.4 Recent strategies and developments:
9.3.4.1 Partnerships, Collaborations, and Agreements:
9.3.4.2 Acquisition and Mergers:
9.3.4.3 Approvals and Trials:
9.4 Bristol Myers Squibb Company
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Acquisition and Mergers:
9.4.5.2 Approvals and Trials:
9.5 Pfizer, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional & Segmental Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.5.5.2 Approvals and Trials:
9.6 AstraZeneca PLC
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.5.3 Approvals and Trials:
9.7 Teva Pharmaceutical Industries Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.8 Eli Lilly And Company
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.5.2 Approvals and Trials:
9.9 Seagen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals and Trials:
9.10. F. Hoffmann-La Roche Ltd.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
TABLE 1 Asia Pacific Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Lymphoma Therapeutics Market
TABLE 4 Product Launches And Product Expansions– Lymphoma Therapeutics Market
TABLE 5 Acquisition and Mergers– Lymphoma Therapeutics Market
TABLE 6 Approvals and trials – Lymphoma Therapeutics Market
TABLE 7 Asia Pacific Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 8 Asia Pacific Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 9 Asia Pacific Immune Therapy Market by Country, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Immune Therapy Market by Country, 2023 - 2029, USD Million
TABLE 11 Asia Pacific Target Therapy Market by Country, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Target Therapy Market by Country, 2023 - 2029, USD Million
TABLE 13 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 15 Asia Pacific Radiation Therapy Market by Country, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Radiation Therapy Market by Country, 2023 - 2029, USD Million
TABLE 17 Asia Pacific Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 19 Asia Pacific Non-Hodgkin Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Non-Hodgkin Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 21 Asia Pacific Hodgkin Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 22 Asia Pacific Hodgkin Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 23 Asia Pacific Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 24 Asia Pacific Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 25 Asia Pacific Injectable Market by Country, 2019 - 2022, USD Million
TABLE 26 Asia Pacific Injectable Market by Country, 2023 - 2029, USD Million
TABLE 27 Asia Pacific Oral Route Market by Country, 2019 - 2022, USD Million
TABLE 28 Asia Pacific Oral Route Market by Country, 2023 - 2029, USD Million
TABLE 29 Asia Pacific Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 30 Asia Pacific Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 31 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 32 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 33 Asia Pacific Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 34 Asia Pacific Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 35 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 36 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 37 Asia Pacific Lymphoma Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 38 Asia Pacific Lymphoma Therapeutics Market by Country, 2023 - 2029, USD Million
TABLE 39 China Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 40 China Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 41 China Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 42 China Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 43 China Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 44 China Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 45 China Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 46 China Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 47 China Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 China Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 49 Japan Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 50 Japan Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 51 Japan Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 52 Japan Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 53 Japan Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 54 Japan Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 55 Japan Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 56 Japan Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 57 Japan Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Japan Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 59 India Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 60 India Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 61 India Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 62 India Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 63 India Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 64 India Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 65 India Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 66 India Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 67 India Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 68 India Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 69 South Korea Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 70 South Korea Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 71 South Korea Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 72 South Korea Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 73 South Korea Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 74 South Korea Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 75 South Korea Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 76 South Korea Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 77 South Korea Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 78 South Korea Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 79 Singapore Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 80 Singapore Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 81 Singapore Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 82 Singapore Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 83 Singapore Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 84 Singapore Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 85 Singapore Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 86 Singapore Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 87 Singapore Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 88 Singapore Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 89 Malaysia Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 90 Malaysia Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 91 Malaysia Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 92 Malaysia Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 93 Malaysia Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 94 Malaysia Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 95 Malaysia Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 96 Malaysia Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 97 Malaysia Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 98 Malaysia Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 99 Rest of Asia Pacific Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 100 Rest of Asia Pacific Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 101 Rest of Asia Pacific Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 102 Rest of Asia Pacific Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 103 Rest of Asia Pacific Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 104 Rest of Asia Pacific Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 105 Rest of Asia Pacific Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 106 Rest of Asia Pacific Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 107 Rest of Asia Pacific Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 108 Rest of Asia Pacific Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 109 Key Information – Bayer AG
TABLE 110 Key information –Johnson & Johnson
TABLE 111 Key Information – Gilead Sciences, Inc.
TABLE 112 Key Information – Bristol Myers Squibb Company
TABLE 113 Key Information – Pfizer, Inc.
TABLE 114 KEY INFORMATION – AstraZeneca PLC
TABLE 115 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 116 Key Information – Eli Lilly And Company
TABLE 117 Key Information – Seagen Inc.
TABLE 118 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Swot analysis: bayer ag
FIG 5 SWOT analysis: Johnson & Johnson
FIG 6 Recent strategies and developments: Gilead Sciences, Inc.
FIG 7 Recent strategies and developments: Bristol Myers Squibb Company
FIG 8 Recent strategies and developments: Pfizer, Inc.
FIG 9 Recent strategies and developments: AstraZeneca PLC